Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the coming five years to bolster its presence ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...